JP2016504403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504403A5 JP2016504403A5 JP2015552095A JP2015552095A JP2016504403A5 JP 2016504403 A5 JP2016504403 A5 JP 2016504403A5 JP 2015552095 A JP2015552095 A JP 2015552095A JP 2015552095 A JP2015552095 A JP 2015552095A JP 2016504403 A5 JP2016504403 A5 JP 2016504403A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid solution
- solution pharmaceutical
- glyceryl
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000006104 solid solution Substances 0.000 claims 24
- 239000007788 liquid Substances 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 10
- 229920000642 polymer Polymers 0.000 claims 6
- 150000003626 triacylglycerols Chemical class 0.000 claims 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000037976 chronic inflammation Diseases 0.000 claims 3
- 230000006020 chronic inflammation Effects 0.000 claims 3
- -1 glyceryl monostearidonic acid Chemical compound 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims 1
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 1
- FABAOYOFJNAVHB-RRABGKBLSA-N (e)-octadec-9-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC\C=C\CCCCCCCC(O)=O FABAOYOFJNAVHB-RRABGKBLSA-N 0.000 claims 1
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 claims 1
- ZXNAIPHYBVMMPY-KTKRTIGZSA-N 1-erucoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCC(O)CO ZXNAIPHYBVMMPY-KTKRTIGZSA-N 0.000 claims 1
- NVQGQHXFWUBOAU-KTKRTIGZSA-N 1-nervonoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)OCC(O)CO NVQGQHXFWUBOAU-KTKRTIGZSA-N 0.000 claims 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 1
- XSQSIJOKSPPKKS-UHFFFAOYSA-N 2,3-dihydroxypropyl docosa-2,4,6,8,10,12-hexaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)OCC(O)CO XSQSIJOKSPPKKS-UHFFFAOYSA-N 0.000 claims 1
- YBDMTIKLNFRWEB-UHFFFAOYSA-N 2,3-dihydroxypropyl icos-2-enoate Chemical compound CCCCCCCCCCCCCCCCCC=CC(=O)OCC(O)CO YBDMTIKLNFRWEB-UHFFFAOYSA-N 0.000 claims 1
- KFWNEOJLDXABRC-UHFFFAOYSA-N 2,3-dihydroxypropyl icosa-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OCC(O)CO KFWNEOJLDXABRC-UHFFFAOYSA-N 0.000 claims 1
- DMCMOFCRZHRTKH-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethanol Chemical compound CCOCCOCCO.CCOCCOCCO DMCMOFCRZHRTKH-UHFFFAOYSA-N 0.000 claims 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- JGYMUQRIGUVTCD-SYJLDBGTSA-N C(C(O)CO)CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O Chemical compound C(C(O)CO)CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O JGYMUQRIGUVTCD-SYJLDBGTSA-N 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010044210 PPAR-beta Proteins 0.000 claims 1
- 235000021319 Palmitoleic acid Nutrition 0.000 claims 1
- 102000019280 Pancreatic lipases Human genes 0.000 claims 1
- 108050006759 Pancreatic lipases Proteins 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 claims 1
- 102000001424 Ryanodine receptors Human genes 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 208000026062 Tissue disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 229940033495 antimalarials Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003720 enoxolone Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- GGJRAQULURVTAJ-UHFFFAOYSA-N glyceryl monolinolenate Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OCC(O)CO GGJRAQULURVTAJ-UHFFFAOYSA-N 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940049918 linoleate Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229940116369 pancreatic lipase Drugs 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- GGJRAQULURVTAJ-PDBXOOCHSA-N rac-1-alpha-linolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(O)CO GGJRAQULURVTAJ-PDBXOOCHSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229930003802 tocotrienol Natural products 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361752356P | 2013-01-14 | 2013-01-14 | |
| US61/752,356 | 2013-01-14 | ||
| US201361752309P | 2013-02-04 | 2013-02-04 | |
| US61/752,309 | 2013-02-04 | ||
| PCT/EP2014/050637 WO2014108573A1 (en) | 2013-01-14 | 2014-01-14 | Solid solution compositions and use in chronic inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504403A JP2016504403A (ja) | 2016-02-12 |
| JP2016504403A5 true JP2016504403A5 (enExample) | 2017-02-16 |
| JP6389190B2 JP6389190B2 (ja) | 2018-09-12 |
Family
ID=50030251
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552094A Active JP6505607B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および心血管疾患における使用 |
| JP2015552095A Active JP6389190B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および慢性炎症における使用 |
| JP2015552096A Active JP6378694B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および激痛における使用 |
| JP2019061720A Pending JP2019116498A (ja) | 2013-01-14 | 2019-03-27 | 固溶体組成物および心血管疾患における使用 |
| JP2021139210A Active JP7250865B2 (ja) | 2013-01-14 | 2021-08-27 | 固溶体組成物および心血管疾患における使用 |
| JP2023045431A Active JP7748411B2 (ja) | 2013-01-14 | 2023-03-22 | 固溶体組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552094A Active JP6505607B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および心血管疾患における使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552096A Active JP6378694B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および激痛における使用 |
| JP2019061720A Pending JP2019116498A (ja) | 2013-01-14 | 2019-03-27 | 固溶体組成物および心血管疾患における使用 |
| JP2021139210A Active JP7250865B2 (ja) | 2013-01-14 | 2021-08-27 | 固溶体組成物および心血管疾患における使用 |
| JP2023045431A Active JP7748411B2 (ja) | 2013-01-14 | 2023-03-22 | 固溶体組成物 |
Country Status (16)
| Country | Link |
|---|---|
| EP (6) | EP2943222B1 (enExample) |
| JP (6) | JP6505607B2 (enExample) |
| KR (6) | KR102491426B1 (enExample) |
| CN (4) | CN104968368B (enExample) |
| AU (4) | AU2014204735B2 (enExample) |
| BR (3) | BR112015015858B1 (enExample) |
| CA (3) | CA2897878A1 (enExample) |
| ES (5) | ES2830033T3 (enExample) |
| IL (5) | IL295091B2 (enExample) |
| MX (3) | MX377877B (enExample) |
| NZ (1) | NZ709486A (enExample) |
| PL (1) | PL3795141T3 (enExample) |
| RU (3) | RU2667977C2 (enExample) |
| SG (4) | SG10201704472QA (enExample) |
| WO (3) | WO2014108572A1 (enExample) |
| ZA (3) | ZA201505002B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| MX377877B (es) * | 2013-01-14 | 2025-03-11 | Infirst Healthcare Ltd | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. |
| CN108025078A (zh) * | 2015-08-07 | 2018-05-11 | 因佛斯特医疗有限公司 | 用于nsaid的固体溶液组合物 |
| US10307388B2 (en) * | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
| AU2018354090B2 (en) | 2017-10-23 | 2024-10-24 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
| AU2019271067B2 (en) * | 2018-05-16 | 2023-08-03 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to aging |
| EP3796976A4 (en) | 2018-05-23 | 2022-03-30 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO LONGEVITY AND QUALITY OF AGING |
| CN108653273A (zh) * | 2018-07-13 | 2018-10-16 | 昆明医科大学第附属医院 | 青蒿素类化合物作为制备治疗贝赫切特病药物的应用 |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| EP3908374A4 (en) | 2019-01-09 | 2022-12-28 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES |
| JP7404382B2 (ja) | 2019-03-04 | 2023-12-25 | エピトラッカー インコーポレイテッド | 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用 |
| CN110251549B (zh) * | 2019-06-24 | 2021-12-03 | 浙江省肿瘤医院 | 淫羊藿总黄酮提取物在制备防治桥本甲状腺炎的药物中的应用 |
| CN114007590A (zh) * | 2019-06-28 | 2022-02-01 | 江苏恒瑞医药股份有限公司 | 一种缓释脂质组合物及其制备方法 |
| NZ780733A (en) * | 2019-07-21 | 2022-08-26 | Scf Pharma Inc | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| ES3039926T3 (en) | 2019-12-04 | 2025-10-27 | Neurocrine Biosciences Inc | Crf receptor antagonists and methods of use |
| EP4100029A4 (en) * | 2020-02-03 | 2024-03-06 | Curemast, Inc. | COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OF MASTITIS |
| RU2752764C1 (ru) * | 2020-12-14 | 2021-08-03 | Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") | Фармацевтическая композиция, обладающая противовоспалительным действием |
| AU2022248850A1 (en) | 2021-03-27 | 2023-11-09 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| JP2024539823A (ja) | 2021-11-03 | 2024-10-31 | エピトラッカー インコーポレイテッド | 老化の質および寿命に関係する状態の治療のためのペンタデカノイルカルニチン |
| JP2023097354A (ja) * | 2021-12-27 | 2023-07-07 | 株式会社 資生堂 | 血管を安定化させるため、または血管のバリア機能を強化するための組成物 |
| CN114601843A (zh) * | 2022-03-22 | 2022-06-10 | 重庆医科大学附属第一医院 | 淫羊藿苷在制备治疗自身免疫性葡萄膜炎药物中的用途 |
| GB202208911D0 (en) * | 2022-06-17 | 2022-08-10 | Ravan Bio Limtied | Treatments |
| CA3264785A1 (en) | 2022-08-12 | 2024-02-15 | Jazz Pharmaceuticals Research Uk Limited | ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| US5143934A (en) * | 1990-11-21 | 1992-09-01 | A/S Dumex (Dumex Ltd.) | Method and composition for controlled delivery of biologically active agents |
| GB9613858D0 (en) * | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
| SI0999826T1 (en) * | 1997-07-29 | 2004-12-31 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB2331458B (en) * | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| KR20020011985A (ko) * | 1999-05-07 | 2002-02-09 | 파르마솔 게엠베하 | 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법 |
| CA2369594A1 (en) * | 1999-05-07 | 2000-11-16 | Pharmasol Gmbh | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
| WO2000076478A1 (en) * | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| WO2001021154A2 (en) * | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
| US6455067B1 (en) * | 2000-05-24 | 2002-09-24 | Sang-A Pharmaceutical Co., Ltd. | Transdermal patch for nonsteroidal antiinflammatory drug(s) |
| JP3763567B2 (ja) * | 2001-01-19 | 2006-04-05 | 株式会社資生堂 | 化粧料 |
| US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| JP2007500691A (ja) * | 2003-07-31 | 2007-01-18 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗炎症剤の分散性製剤 |
| KR20060085686A (ko) * | 2003-10-10 | 2006-07-27 | 라이프사이클 파마 에이/에스 | 피브레이트를 포함하는 고형 제제 |
| KR20060118536A (ko) * | 2003-11-13 | 2006-11-23 | 콤비네이토릭스, 인코포레이티드 | 면역염증성 질환의 치료 방법 및 시약 |
| EP1694305B1 (en) * | 2003-12-01 | 2019-10-16 | Recordati Ireland Limited | Pharmaceutical compositions comprising lercanidipine |
| WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| CA2560613C (en) * | 2004-03-22 | 2015-11-24 | Solvay Pharmaceuticals Gmbh | Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
| AU2005309808A1 (en) * | 2004-11-24 | 2006-06-01 | Merck & Co., Inc. | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
| AU2006240551A1 (en) * | 2005-04-28 | 2006-11-02 | Dsm Ip Assets B.V. | Pharmaceutical dosage forms comprising a lipid phase |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| GB0704846D0 (en) * | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| RU2353349C2 (ru) * | 2007-04-18 | 2009-04-27 | Общество с ограниченной ответственностью "Фармацевтические технологии" | Средство для лечения болезней суставов |
| CN101129335B (zh) * | 2007-07-17 | 2010-09-22 | 浙江大学 | 一种纳米结构脂质载体给药系统的用途 |
| ES2423793T3 (es) | 2008-05-26 | 2013-09-24 | Genfit | Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias |
| GB201018289D0 (en) * | 2010-10-29 | 2010-12-15 | Biocopea Ltd | Treatment of respiratory disorders |
| WO2012104655A2 (en) * | 2011-02-04 | 2012-08-09 | Biocopea Limited | Compostions and methods for treating chronic inflammation and inflammatory diseases |
| CN103442700B (zh) * | 2011-03-24 | 2016-04-06 | 利奥制药有限公司 | 含有脂质纳米颗粒和皮质类固醇或维生素d衍生物的组合物 |
| CN102793628B (zh) * | 2012-08-23 | 2014-07-02 | 东华大学 | 用于化妆品的液-固混合脂质纳米缓释系统及其制备方法 |
| MX377877B (es) * | 2013-01-14 | 2025-03-11 | Infirst Healthcare Ltd | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. |
-
2014
- 2014-01-14 MX MX2015009106A patent/MX377877B/es unknown
- 2014-01-14 KR KR1020217040230A patent/KR102491426B1/ko active Active
- 2014-01-14 ES ES14703279T patent/ES2830033T3/es active Active
- 2014-01-14 MX MX2015009105A patent/MX379193B/es unknown
- 2014-01-14 RU RU2015134142A patent/RU2667977C2/ru active IP Right Revival
- 2014-01-14 PL PL20192758.9T patent/PL3795141T3/pl unknown
- 2014-01-14 EP EP14701930.1A patent/EP2943222B1/en active Active
- 2014-01-14 AU AU2014204735A patent/AU2014204735B2/en active Active
- 2014-01-14 IL IL295091A patent/IL295091B2/en unknown
- 2014-01-14 CN CN201480006216.7A patent/CN104968368B/zh active Active
- 2014-01-14 SG SG10201704472QA patent/SG10201704472QA/en unknown
- 2014-01-14 BR BR112015015858-7A patent/BR112015015858B1/pt active IP Right Grant
- 2014-01-14 BR BR112015015891-9A patent/BR112015015891B1/pt active IP Right Grant
- 2014-01-14 AU AU2014204734A patent/AU2014204734B2/en active Active
- 2014-01-14 RU RU2015134141A patent/RU2675241C2/ru active IP Right Revival
- 2014-01-14 WO PCT/EP2014/050636 patent/WO2014108572A1/en not_active Ceased
- 2014-01-14 JP JP2015552094A patent/JP6505607B2/ja active Active
- 2014-01-14 NZ NZ709486A patent/NZ709486A/en unknown
- 2014-01-14 CN CN201480006298.5A patent/CN104981253B/zh active Active
- 2014-01-14 IL IL282123A patent/IL282123B/en unknown
- 2014-01-14 EP EP21164383.8A patent/EP3858335A1/en active Pending
- 2014-01-14 KR KR1020157021075A patent/KR20150125648A/ko not_active Ceased
- 2014-01-14 KR KR1020157021076A patent/KR102235264B1/ko active Active
- 2014-01-14 CA CA2897878A patent/CA2897878A1/en not_active Abandoned
- 2014-01-14 CN CN201480006940.XA patent/CN105007947B/zh active Active
- 2014-01-14 KR KR1020237002149A patent/KR20230017914A/ko not_active Ceased
- 2014-01-14 WO PCT/EP2014/050638 patent/WO2014108574A1/en not_active Ceased
- 2014-01-14 EP EP14702460.8A patent/EP2925367B1/en active Active
- 2014-01-14 KR KR1020217009229A patent/KR102338569B1/ko active Active
- 2014-01-14 JP JP2015552095A patent/JP6389190B2/ja active Active
- 2014-01-14 SG SG11201505249VA patent/SG11201505249VA/en unknown
- 2014-01-14 CA CA2897884A patent/CA2897884C/en active Active
- 2014-01-14 ES ES14701930T patent/ES2829904T3/es active Active
- 2014-01-14 JP JP2015552096A patent/JP6378694B2/ja active Active
- 2014-01-14 ES ES20192758T patent/ES3041421T3/es active Active
- 2014-01-14 EP EP19188174.7A patent/EP3578172B1/en active Active
- 2014-01-14 AU AU2014204737A patent/AU2014204737B2/en active Active
- 2014-01-14 RU RU2015134143A patent/RU2674982C2/ru active IP Right Revival
- 2014-01-14 ES ES14702460T patent/ES2763352T3/es active Active
- 2014-01-14 WO PCT/EP2014/050637 patent/WO2014108573A1/en not_active Ceased
- 2014-01-14 MX MX2015009104A patent/MX377340B/es active IP Right Grant
- 2014-01-14 SG SG11201505247TA patent/SG11201505247TA/en unknown
- 2014-01-14 KR KR1020157021073A patent/KR102252574B1/ko active Active
- 2014-01-14 EP EP20192758.9A patent/EP3795141B1/en active Active
- 2014-01-14 SG SG11201505241WA patent/SG11201505241WA/en unknown
- 2014-01-14 ES ES19188174T patent/ES2875824T3/es active Active
- 2014-01-14 CN CN201910070081.5A patent/CN109549927B/zh active Active
- 2014-01-14 EP EP14703279.1A patent/EP2943223B1/en active Active
- 2014-01-14 BR BR112015015898-6A patent/BR112015015898B1/pt active IP Right Grant
- 2014-01-14 CA CA2898000A patent/CA2898000A1/en not_active Abandoned
-
2015
- 2015-07-13 ZA ZA2015/05002A patent/ZA201505002B/en unknown
- 2015-07-13 ZA ZA2015/05003A patent/ZA201505003B/en unknown
- 2015-07-13 ZA ZA2015/05004A patent/ZA201505004B/en unknown
- 2015-07-14 IL IL239923A patent/IL239923A0/en unknown
- 2015-07-14 IL IL239922A patent/IL239922B/en active IP Right Grant
- 2015-07-14 IL IL239924A patent/IL239924A0/en unknown
-
2016
- 2016-11-11 AU AU2016256804A patent/AU2016256804B2/en active Active
-
2019
- 2019-03-27 JP JP2019061720A patent/JP2019116498A/ja active Pending
-
2021
- 2021-08-27 JP JP2021139210A patent/JP7250865B2/ja active Active
-
2023
- 2023-03-22 JP JP2023045431A patent/JP7748411B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508155A5 (enExample) | ||
| JP2016505625A5 (enExample) | ||
| JP2016506941A5 (enExample) | ||
| RU2015134141A (ru) | Композиции твердых растворов и их применение при хроническом воспалении | |
| JP2016504401A5 (enExample) | ||
| AR084639A1 (es) | Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| JP2018526351A5 (enExample) | ||
| UY33044A (es) | Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos | |
| MX392440B (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| EP2552203A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| HRP20201043T1 (hr) | Spojevi 4-amino-imidazokinolina | |
| EA201100863A1 (ru) | Фармацевтическая композиция, включающая диклофенак и сложный эфир гидроксижирной кислоты и полиоксиалкилена | |
| UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
| RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента | |
| JP2016511753A5 (enExample) | ||
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| JP2014509655A5 (enExample) | ||
| JP2015506363A5 (enExample) | ||
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение | |
| MX383762B (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| JP2013528656A5 (enExample) |